Comparative Pharmacology
Head-to-head clinical analysis: BOSENTAN versus LETAIRIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSENTAN versus LETAIRIS.
BOSENTAN vs LETAIRIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Endothelin receptor antagonist; blocks endothelin-1 (ET-1) from binding to ETA and ETB receptors, inhibiting vasoconstriction and proliferation.
Ambrisentan is an endothelin receptor antagonist that selectively inhibits endothelin-1 (ET-1) binding to endothelin type A (ETA) receptors in pulmonary vascular smooth muscle cells, reducing vasoconstriction and smooth muscle proliferation.
62.5 mg orally twice daily for 4 weeks, then increase to maintenance dose of 125 mg twice daily.
5 mg orally once daily, with or without food; may increase to 10 mg once daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours in healthy adults, but prolonged in patients with hepatic impairment (up to 21 hours in Child-Pugh Class A and B).
Clinical Note
moderateBosentan + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Bosentan."
Clinical Note
moderateBosentan + Torasemide
"Bosentan may increase the hypotensive activities of Torasemide."
Clinical Note
moderateBosentan + Estrone sulfate
Terminal elimination half-life is approximately 9 hours (range 6–12 hours) in healthy adults.
Primarily biliary excretion (≥50% as unchanged drug) with fecal elimination; renal excretion accounts for <3% of unchanged drug.
Primarily via biliary/fecal elimination (approximately 80% of metabolites and unchanged drug; ~20% renal as metabolites).
Category D/X
Category C
Endothelin Receptor Antagonist
Endothelin Receptor Antagonist
"The serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan."